{
  "meta": {
    "title": "00025_Mid_Day_Module_Medicine-8",
    "url": "https://brainandscalpel.vercel.app/00025-mid-day-module-medicine-8-034bfd09.html",
    "scrapedAt": "2025-11-29T18:11:57.750Z"
  },
  "questions": [
    {
      "id": 20636,
      "choices": [
        {
          "id": 82507,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">0.5 mg </span></span></span></p>"
        },
        {
          "id": 82508,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1 mg </span></span></span></p>"
        },
        {
          "id": 82509,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1.4 mg </span></span></span></p>"
        },
        {
          "id": 82510,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">2 mg</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a healthy adult male, the average daily iron absorption from dietary sources is approximately:</span></span></p>",
      "unique_key": "Q8342379",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507516,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 1 mg</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adult men typically require about ~1 mg of iron to be absorbed from the diet daily to maintain iron balance and replace losses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron Absorption of ~1mg/d is required from the diet in men, and 1.4mg/d in women to maintain homeostasis.</span></span></span></p>",
      "correct_choice_id": 82508,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20640,
      "choices": [
        {
          "id": 82523,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ascorbic acid </span></span></span></p>"
        },
        {
          "id": 82524,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Orange juice </span></span></span></p>"
        },
        {
          "id": 82525,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Meat </span></span></span></p>"
        },
        {
          "id": 82526,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antacids</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following substances can IMPAIR the absorption of iron supplements?</span></span></span></p>",
      "unique_key": "Q9183200",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507517,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Antacids</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antacids neutralize stomach acid, which is necessary for the conversion of ferric iron (Fe3+) to ferrous iron (Fe2+), the form that is more readily absorbed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option (A, B, C):</span></strong><span style=\"font-size:12.0pt\"> Vitamin C (in <strong>ascorbic acid</strong> and <strong>orange juice)</strong> and <strong>meat</strong> can all improve iron absorption.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients taking iron supplements should avoid taking antacids concurrently, as this can reduce absorption.</span></span></span></p>",
      "correct_choice_id": 82526,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20654,
      "choices": [
        {
          "id": 82579,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Within 24-48 hours of starting therapy </span></span></span></p>"
        },
        {
          "id": 82580,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3-4 days after starting therapy </span></span></span></p>"
        },
        {
          "id": 82581,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">7-10 days after starting therapy </span></span></span></p>"
        },
        {
          "id": 82582,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">14-21 days after starting therapy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with iron deficiency anemia is started on oral iron supplementation. When would you expect to see the PEAK reticulocyte response, indicating that the bone marrow is actively producing new red blood cells?</span></span></p>",
      "unique_key": "Q3811305",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507518,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) 7-10 days after starting therapy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The peak reticulocyte response typically occurs within 1-1.5 weeks (7-10 days) after starting iron therapy. This indicates a robust response from the bone marrow to correct the anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong> <strong><span style=\"font-size:12.0pt\">Within 24-48 hours of starting therapy:</span></strong><span style=\"font-size:12.0pt\"> This is too soon to expect a peak response. It takes several days for the bone marrow to ramp up red blood cell production.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 3-4 days after starting therapy:</span></strong><span style=\"font-size:12.0pt\"> While the reticulocyte count may start to rise within 3-4 days, the peak response is typically later.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 14-21 days after starting therapy:</span></strong><span style=\"font-size:12.0pt\"> This is too late for the peak response. If there&#39;s no significant increase by this time, it could suggest a lack of response to therapy or an alternative diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The reticulocyte count is a valuable tool for monitoring the response to iron therapy in iron deficiency anemia. An increase in reticulocytes within 4-7 days and a peak response at 7-10 days are expected findings, indicating that the treatment is effective.</span></span></span></p>",
      "correct_choice_id": 82581,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20686,
      "choices": [
        {
          "id": 82707,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&alpha;&alpha;/&alpha;&alpha; </span></span></span></p>"
        },
        {
          "id": 82708,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">-&alpha;/&alpha;&alpha; </span></span></span></p>"
        },
        {
          "id": 82709,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">--/&alpha;&alpha; </span></span></span></p>"
        },
        {
          "id": 82710,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">--/-&alpha;</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following alpha-globin gene arrangements is MOST likely to be associated with Hemoglobin H (HbH) disease?</span></span></span></p>",
      "unique_key": "Q7990462",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507519,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) --/-&alpha;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbH disease is caused by the deletion or inactivation of three out of four alpha-globin genes. The genotype &quot;--/-&alpha;&quot; represents this condition, where one chromosome has both alpha-globin genes deleted, and the other chromosome has one alpha-globin gene deleted.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. &alpha;&alpha;/&alpha;&alpha;:&nbsp;</span></strong><span style=\"font-size:12.0pt\">&alpha;-thal.</span><strong> </strong><span style=\"font-size:12.0pt\">With Myelodysplasia - </span><span style=\"font-size:12.0pt\">Mutations in <em>ATRX</em>; striking male predominance. Hematologic findings of HbH disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong> <strong><span style=\"font-size:12.0pt\">-&alpha;/&alpha;&alpha;:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Represents the silent carrier state of alpha-thalassemia, with only one alpha-globin gene deleted. It typically doesn&#39;t cause significant clinical symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong> <strong><span style=\"font-size:12.0pt\">--/&alpha;&alpha;:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Represents alpha-thalassemia trait, where two alpha-globin genes are deleted. This condition can lead to mild anemia but is not associated with HbH disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The specific arrangement and number of alpha-globin gene deletions determine the severity of alpha-thalassemia. HbH disease, a moderate form of the condition, is caused by the deletion or inactivation of three out of four alpha-globin genes, represented by the genotype --/-&alpha; (other gene arrangement: &alpha;<sup>T</sup>&alpha;/- -, &alpha;<sup>T</sup>&alpha;/&alpha;<sup>T</sup>&alpha;)</span></span></span></p>",
      "correct_choice_id": 82710,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20692,
      "choices": [
        {
          "id": 82731,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron deficiency anemia </span></span></span></p>"
        },
        {
          "id": 82732,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin B12 deficiency </span></span></span></p>"
        },
        {
          "id": 82733,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sickle cell anemia </span></span></span></p>"
        },
        {
          "id": 82734,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-thalassemia intermedia</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman with a history of mild anemia on routine blood work presents for a follow-up appointment. She reports good energy levels and denies any recent illnesses or blood loss. Her physical examination is unremarkable. A peripheral blood smear is shown in the image. Which of the following hematological conditions is MOST likely represented in this blood smear?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/31/screenshot-2024-07-31-124914.png\" style=\"height:151px; width:300px\" /></span></span></p>",
      "unique_key": "Q1199028",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507520,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. D) Beta-thalassemia intermedia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image shows target cells and marked variation in cell size (anisocytosis) and shape (poikilocytosis), along with hypochromia (pale red blood cells) and microcytosis (small red blood cells). These are hallmark features of beta-thalassemia intermedia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Iron deficiency anemia:</span></strong><span style=\"font-size:12.0pt\"> While also microcytic and hypochromic, it usually does not exhibit target cells or the degree of poikilocytosis seen here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Vitamin B12 deficiency:</span></strong><span style=\"font-size:12.0pt\"> Causes macrocytic (large red blood cell) anemia, not microcytic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sickle cell anemia:</span></strong><span style=\"font-size:12.0pt\"> Characterized by sickle-shaped red blood cells, which are not present in this image.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of target cells, anisocytosis, poikilocytosis, hypochromia and microcytosis in a blood smear strongly suggests beta-thalassemia intermedia.</span></span></span></p>",
      "correct_choice_id": 82734,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20696,
      "choices": [
        {
          "id": 82747,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive direct antiglobulin test (DAT) with anti-IgG specificity </span></span></span></p>"
        },
        {
          "id": 82748,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive DAT with anti-C3d specificity </span></span></span></p>"
        },
        {
          "id": 82749,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive DAT with anti-IgM specificity </span></span></span></p>"
        },
        {
          "id": 82750,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Negative DAT</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presents with anemia and acrocyanosis that worsens in cold weather. Which of the following laboratory findings is most consistent with cold agglutinin syndrome (CAS)?</span></span></p>",
      "unique_key": "Q1149006",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507521,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Positive DAT with anti-IgM specificity</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CAS is caused by IgM autoantibodies that bind to red blood cells at low temperatures, leading to agglutination and hemolysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Positive direct antiglobulin test (DAT) with anti-IgG specificity&nbsp;</span></strong><span style=\"font-size:12.0pt\">and <strong>Option</strong> <strong>B. Positive DAT with anti-C3d specificity</strong> are more commonly associated with WAIHA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Negative DAT</strong>:</span><strong><span style=\"font-size:12.0pt\">&nbsp;</span></strong><span style=\"font-size:12.0pt\">A negative DAT would not be expected in a patient with autoimmune hemolytic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A positive DAT with anti-IgM specificity is a key laboratory finding in the diagnosis of CAS.</span></span></span></p>",
      "correct_choice_id": 82749,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20698,
      "choices": [
        {
          "id": 82755,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cold agglutinin disease (CAD) </span></span></span></p>"
        },
        {
          "id": 82756,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paroxysmal cold hemoglobinuria (PCH) </span></span></span></p>"
        },
        {
          "id": 82757,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Warm autoimmune hemolytic anemia (WAIHA) </span></span></span></p>"
        },
        {
          "id": 82758,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microangiopathic hemolytic anemia (MAHA)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old man with a history of lymphoma presents with fatigue, jaundice, and splenomegaly. Peripheral blood smear shows spherocytes. Which of the following is the MOST likely diagnosis?</span></span></p>",
      "unique_key": "Q7585563",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507522,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Warm autoimmune hemolytic anemia (WAIHA)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation of fatigue, jaundice, and splenomegaly, along with spherocytes on peripheral smear, is most consistent with WAIHA. The history of lymphoma increases the likelihood of WAIHA, as some types of lymphoma can trigger autoimmune responses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cold agglutinin disease (CAD):&nbsp;</span></strong><span style=\"font-size:12.0pt\">Primarily presents with acrocyanosis and anemia, and blood smear often reveals agglutination.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Paroxysmal cold hemoglobinuria (PCH):&nbsp;</span></strong><span style=\"font-size:12.0pt\">Paroxysmal cold hemoglobinuria (PCH)&nbsp;is rare and typically presents with biphasic hemolysis and hemoglobinuria after cold exposure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Microangiopathic hemolytic anemia (MAHA):</span></strong><span style=\"font-size:12.0pt\"> Presents with schistocytes on peripheral smear and is associated with underlying conditions like thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">WAIHA is the most common type of autoimmune hemolytic anemia and can be associated with underlying lymphoproliferative disorders like lymphoma</span></span></span></p>",
      "correct_choice_id": 82757,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20766,
      "choices": [
        {
          "id": 83027,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increasing fetal hemoglobin (HbF) levels </span></span></span></p>"
        },
        {
          "id": 83028,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreasing red blood cell sickling </span></span></span></p>"
        },
        {
          "id": 83029,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibiting platelet aggregation </span></span></span></p>"
        },
        {
          "id": 83030,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Blocking adhesive interactions between sickle cells and endothelial cells</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old patient with sickle cell disease (SCD) and a history of frequent vaso-occlusive crises is being considered for treatment with crizanlizumab, a monoclonal antibody that targets P-selectin. What is the PRIMARY mechanism of action of crizanlizumab in preventing vaso-occlusive crises in SCD?</span></span></p>",
      "unique_key": "Q7522689",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507523,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Blocking adhesive interactions between sickle cells and endothelial cells</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Crizanlizumab, a P-selectin inhibitor, works by preventing the adhesion of sickle cells to the endothelium, thereby reducing the risk of vaso-occlusion and subsequent painful crises.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increasing fetal hemoglobin (HbF) levels:</span></strong><span style=\"font-size:12.0pt\"> Hydroxyurea, not crizanlizumab, is the primary medication used to increase HbF levels in sickle cell disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Decreasing red blood cell sickling:</span></strong><span style=\"font-size:12.0pt\"> While reducing adhesion can indirectly help prevent sickling, crizanlizumab&#39;s primary mechanism is not directly targeting the sickling process itself.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inhibiting platelet aggregation:</span></strong><span style=\"font-size:12.0pt\"> While platelets play a role in vaso-occlusion, crizanlizumab&#39;s primary target is P-selectin on endothelial cells, not platelets.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">P-selectin blockade is a novel therapeutic approach in SCD that targets the adhesive interactions involved in vaso-occlusion.</span></span></span></p>",
      "correct_choice_id": 83030,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20767,
      "choices": [
        {
          "id": 83031,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbC only</span></span></span></p>"
        },
        {
          "id": 83032,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA and HbC</span></span></span></p>"
        },
        {
          "id": 83033,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA and HbS</span></span></span></p>"
        },
        {
          "id": 83034,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbS and HbC</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An&nbsp;11-year-old&nbsp;boy is brought to the physician by his mother because of worsening&nbsp;fatigue. His mother reports that he seems to have trouble keeping up with his older brothers when playing outside. Physical examination shows&nbsp;conjunctival pallor. A&nbsp;hemoglobin electrophoresis&nbsp;is performed. This patient&#39;s results are shown in comparison to those of a patient with known sickle cell anemia and a child with normal hemoglobin. Based on this electrophoresis, which of the following types of hemoglobin are dominant in this patient&#39;s blood?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/31/whatsapp-image-2024-07-31-at-50300-pm.jpeg\" style=\"height:484px; width:200px\" /></p>",
      "unique_key": "Q5759883",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507524,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) HbS and HbC</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA&nbsp;(&alpha;<sub>2</sub>&beta;<sub>2</sub>), which is the predominant form of&nbsp;hemoglobin&nbsp;by the age of 6 months, migrates farther than&nbsp;HbS, which is the predominant&nbsp;hemoglobin&nbsp;of patients with&nbsp;sickle cell disease. This is because&nbsp;HbS&nbsp;contains a neutral&nbsp;valine&nbsp;residue at&nbsp;position 6 within the beta subunit in place of the normal, negatively charged&nbsp;glutamic acid&nbsp;residue.&nbsp;HbS, in turn, migrates farther than&nbsp;HbC&nbsp;because&nbsp;HbC&nbsp;contains a positively charged&nbsp;lysine&nbsp;residue in the same position. The thin band between&nbsp;HbS&nbsp;and&nbsp;HbA&nbsp;in the&nbsp;sickle cell&nbsp;patient&#39;s sample is&nbsp;HbF&nbsp;(&alpha;<sub>2</sub>&gamma;<sub>2</sub>), which is slightly less negatively charged than&nbsp;HbA&nbsp;but more negatively charged than&nbsp;HbS.&nbsp;HbF&nbsp;is normally present in negligible quantities by early childhood but patients with&nbsp;sickle cell disease&nbsp;often have increased levels of&nbsp;HbF. This patient&#39;s&nbsp;hemoglobin electrophoresis&nbsp;shows one band at the position of the&nbsp;HbS&nbsp;band and the other at a position closer to the cathode than&nbsp;HbS. Therefore, this patient has&nbsp;HbSC disease.&nbsp;HbSC&nbsp;patients have milder symptoms than those with&nbsp;homozygous&nbsp;sickle cell anemia&nbsp;(HbSS).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. HbC only:</span></strong><span style=\"font-size:12.0pt\"> Individuals&nbsp;homozygous&nbsp;for&nbsp;HbC&nbsp;have&nbsp;hemoglobin C disease, which typically manifests with mild&nbsp;anemia. The electrophoresis pattern of a patient with&nbsp;HbC disease&nbsp;would show a single thicker band that migrates even less than&nbsp;HbS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. HbA and HbC:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Individuals with the&nbsp;hemoglobin C&nbsp;trait would have both&nbsp;HbA&nbsp;and&nbsp;HbC&nbsp;in their blood.&nbsp;Hemoglobin electrophoresis&nbsp;of this patient shows&nbsp;HbC&nbsp;but not&nbsp;HbA. Moreover,&nbsp;hemoglobin C&nbsp;trait is usually an asymptomatic carrier state, unlike this patient with fatigue.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. HbA and HbS:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Individuals&nbsp;heterozygous&nbsp;for the&nbsp;sickle cell trait&nbsp;would have both&nbsp;HbA&nbsp;and&nbsp;HbS&nbsp;in their blood.&nbsp;Hemoglobin electrophoresis&nbsp;of this patient shows&nbsp;HbS&nbsp;but not&nbsp;HbA. Moreover, individuals&nbsp;heterozygous&nbsp;for the&nbsp;sickle cell trait&nbsp;are usually asymptomatic, unlike this patient with fatigue.</span></span></span></p>",
      "correct_choice_id": 83034,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20769,
      "choices": [
        {
          "id": 83039,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glutamic acid to lysine </span></span></span></p>"
        },
        {
          "id": 83040,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Valine to glutamic acid </span></span></span></p>"
        },
        {
          "id": 83041,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lysine to glutamic acid </span></span></span></p>"
        },
        {
          "id": 83042,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glutamic acid to valine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old African American woman presents with mild anemia and complains of intermittent abdominal pain. On peripheral blood smear, target cells and rhomboid crystals are noted within red blood cells. Given the likely diagnosis, Which of the following amino acid changes is responsible for this condition?</span></span></p>",
      "unique_key": "Q9116270",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507525,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Glutamic acid to lysine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbC disease is caused by the substitution of glutamic acid with lysine at the sixth position of the beta-globin chain. This change leads to the formation of HbC crystals, which can cause mild to moderate hemolytic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Valine to glutamic acid:</span></strong><span style=\"font-size:12.0pt\"> This substitution is the characteristic change for sickle cell anemia (HbS). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lysine to glutamic acid:</span></strong><span style=\"font-size:12.0pt\"> Swapping these two positively charged amino acids would likely have a minimal effect on hemoglobin function. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Glutamic acid to valine:</span></strong><span style=\"font-size:12.0pt\"> This substitution is also seen in HbS and leads to the polymerization of red blood cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbC disease is a milder form of hemoglobinopathy compared to sickle cell disease, but it is important to distinguish it based on the specific amino acid substitution.</span></span></span></p>",
      "correct_choice_id": 83039,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20773,
      "choices": [
        {
          "id": 83055,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acetaminophen </span></span></span></p>"
        },
        {
          "id": 83056,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Penicillin </span></span></span></p>"
        },
        {
          "id": 83057,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ciprofloxacin </span></span></span></p>"
        },
        {
          "id": 83058,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nitrofurantoin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old woman with G6PD deficiency presents with jaundice and fatigue. Her laboratory results show hemoglobin of 8 g/dL and elevated indirect bilirubin. Which of the following medications would be MOST likely to trigger this hemolytic episode?</span></span></p>",
      "unique_key": "Q1995812",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507526,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Nitrofurantoin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nitrofurantoin is a known oxidant stressor that can trigger hemolysis in individuals with G6PD deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><span style=\"font-size:12.0pt\">&nbsp;<strong>Acetaminophen</strong>:&nbsp;</span><span style=\"font-size:12.0pt\">Acetaminophen is not a common trigger of G6PD deficiency-related hemolysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Penicillin</strong>:&nbsp;</span><span style=\"font-size:12.0pt\">Penicillin is generally safe in G6PD deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Ciprofloxacin</strong>:&nbsp;</span><span style=\"font-size:12.0pt\">Ciprofloxacin is not a common trigger of G6PD deficiency-related hemolysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is crucial to avoid medications that can trigger hemolysis in patients with G6PD deficiency.</span></span></span></p>",
      "correct_choice_id": 83058,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20778,
      "choices": [
        {
          "id": 83075,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased cholesterol secretion </span></span></span></p>"
        },
        {
          "id": 83076,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased bile acid synthesis </span></span></span></p>"
        },
        {
          "id": 83077,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased pigment excretion </span></span></span></p>"
        },
        {
          "id": 83078,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased gallbladder motility</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 15-year-old girl with hereditary spherocytosis presents with right upper quadrant pain. Ultrasound reveals gallstones. Which of the following is the most likely mechanism of gallstone formation in this patient?</span></span></span></p>",
      "unique_key": "Q1256244",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507527,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Increased pigment excretion</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic hemolysis in hereditary spherocytosis leads to increased bilirubin production and excretion, which can promote the formation of pigment gallstones.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increased cholesterol secretion:</span></strong><span style=\"font-size:12.0pt\"> While cholesterol is a major component of gallstones, increased secretion is not the primary culprit in HS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Decreased bile acid synthesis:</span></strong><span style=\"font-size:12.0pt\"> Decreased bile acid synthesis can promote cholesterol gallstones, but it is not a major factor in pigment gallstone formation seen in HS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Decreased gallbladder motility:</span></strong><span style=\"font-size:12.0pt\"> Decreased gallbladder motility can contribute to gallstone formation, but it is not the most specific or common finding in HS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gallstones are a common complication of hereditary spherocytosis due to increased pigment excretion.</span></span></span></p>",
      "correct_choice_id": 83077,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20780,
      "choices": [
        {
          "id": 83083,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Autoimmune hemolytic anemia </span></span></span></p>"
        },
        {
          "id": 83084,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucose-6-phosphate dehydrogenase (G6PD) deficiency </span></span></span></p>"
        },
        {
          "id": 83085,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paroxysmal nocturnal hemoglobinuria (PNH) </span></span></span></p>"
        },
        {
          "id": 83086,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sickle cell disease</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old man presents with fatigue, abdominal pain, and dark urine, especially in the morning. Laboratory tests reveal hemoglobinuria and decreased levels of CD55 and CD59 on red blood cells. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q1475827",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507528,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Paroxysmal nocturnal hemoglobinuria (PNH)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The classic triad of symptoms (fatigue, abdominal pain, and dark urine), along with decreased CD55 and CD59 levels on red blood cells, are characteristic of PNH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Autoimmune hemolytic anemia:</span></strong><span style=\"font-size:12.0pt\"> While it can present with anemia and hemolysis, it typically does not cause hemoglobinuria or have decreased CD55/CD59 levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glucose-6-phosphate dehydrogenase (G6PD) deficiency:</span></strong><span style=\"font-size:12.0pt\"> This usually presents with episodic hemolysis triggered by oxidative stress, not specifically at night.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sickle cell disease:</span></strong><span style=\"font-size:12.0pt\"> This is a genetic hemoglobinopathy with distinct clinical and laboratory findings.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PNH is a rare acquired hemolytic anemia characterized by intravascular hemolysis, often more pronounced at night, and decreased CD55 and CD59 levels on blood cells.</span></span></span></p>",
      "correct_choice_id": 83085,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20788,
      "choices": [
        {
          "id": 83115,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prednisone </span></span></span></p>"
        },
        {
          "id": 83116,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ravulizumab </span></span></span></p>"
        },
        {
          "id": 83117,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab </span></span></span></p>"
        },
        {
          "id": 83118,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cyclosporine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH)?</span></span></p>",
      "unique_key": "Q3946276",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507529,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Ravulizumab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eculizumab and ravulizumab are monoclonal antibodies that inhibit complement activation, the underlying mechanism of hemolysis in PNH. They are the first-line treatment options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Prednisone:</span></strong><span style=\"font-size:12.0pt\"> While corticosteroids like prednisone may be used in some cases of autoimmune hemolytic anemia, they are not the first-line treatment for PNH. They are less effective than eculizumab or ravulizumab at controlling hemolysis and thrombosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Rituximab:</span></strong><span style=\"font-size:12.0pt\"> Rituximab is a monoclonal antibody that targets B cells. While it can be used in some autoimmune disorders, it is not indicated for PNH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cyclosporine:</span></strong><span style=\"font-size:12.0pt\"> Cyclosporine is an immunosuppressant used in various conditions, including organ transplantation and some autoimmune disorders. It has no direct effect on the complement system, which is the primary driver of PNH, and thus is not used in its treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eculizumab and ravulizumab have revolutionized the treatment of PNH by significantly reducing hemolysis, thrombosis risk, and improving quality of life.</span></span></span></p>",
      "correct_choice_id": 83116,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20790,
      "choices": [
        {
          "id": 83123,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased CD34+ cells </span></span></span></p>"
        },
        {
          "id": 83124,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased or absent CD34+ cells </span></span></span></p>"
        },
        {
          "id": 83125,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased blasts </span></span></span></p>"
        },
        {
          "id": 83126,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Monoclonal B-cell population</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Flow cytometry in a patient with suspected aplastic anemia is most likely to reveal:</span></span></span></p>",
      "unique_key": "Q3529497",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507530,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Decreased or absent CD34+ cells</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD34+ cells are hematopoietic stem and progenitor cells. Their decrease or absence reflects the bone marrow failure in aplastic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increased CD34+ cells:</span></strong><span style=\"font-size:12.0pt\"> This would be seen in conditions with increased hematopoietic activity, such as recovery from chemotherapy or certain leukemias. It&#39;s not expected in aplastic anemia where the bone marrow is failing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increased blasts:</span></strong><span style=\"font-size:12.0pt\"> Increased blasts (immature blood cells) would suggest acute leukemia or myelodysplastic syndrome (MDS), not aplastic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Monoclonal B-cell population:</span></strong><span style=\"font-size:12.0pt\"> This finding would be more indicative of a lymphoproliferative disorder, such as chronic lymphocytic leukemia (CLL) or lymphoma, rather than aplastic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Flow cytometry can help confirm the diagnosis of aplastic anemia by demonstrating a lack of CD34+ cells.</span></span></span></p>",
      "correct_choice_id": 83124,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20792,
      "choices": [
        {
          "id": 83131,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microcytic anemia and normal methylmalonic acid (MMA) level </span></span></span></p>"
        },
        {
          "id": 83132,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Macrocytic anemia and elevated MMA level </span></span></span></p>"
        },
        {
          "id": 83133,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Macrocytic anemia and normal MMA level </span></span></span></p>"
        },
        {
          "id": 83134,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normocytic anemia and elevated homocysteine level</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old vegan presents with fatigue, pallor, and numbness and tingling in their hands and feet. Which of the following laboratory findings would be MOST consistent with the suspected diagnosis?</span></span></p>",
      "unique_key": "Q8122319",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507531,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Macrocytic anemia and elevated MMA level</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation (fatigue, pallor, neurological symptoms) and vegan diet strongly suggest vitamin B12 deficiency. Macrocytic anemia is a hallmark of B12 deficiency, and elevated MMA levels are specific for this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Microcytic anemia and normal methylmalonic acid (MMA) level:</span></strong><span style=\"font-size:12.0pt\"> Microcytic anemia is associated with iron deficiency, not B12 deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Macrocytic anemia and normal MMA level:</span></strong><span style=\"font-size:12.0pt\"> While macrocytic anemia is consistent with B12 deficiency, normal MMA levels would not be expected.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Normocytic anemia and elevated homocysteine level:</span></strong><span style=\"font-size:12.0pt\"> Normocytic anemia is not typical of B12 deficiency, and while homocysteine can be elevated in both B12 and folate deficiencies, it&#39;s not specific for B12.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin B12 deficiency should be suspected in vegans presenting with neurological symptoms and macrocytic anemia. Elevated MMA levels are a specific marker for B12 deficiency.</span></span></span></p>",
      "correct_choice_id": 83132,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20795,
      "choices": [
        {
          "id": 83143,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin </span></span></span></p>"
        },
        {
          "id": 83144,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metformin </span></span></span></p>"
        },
        {
          "id": 83145,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate </span></span></span></p>"
        },
        {
          "id": 83146,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atorvastatin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following medications is MOST likely to interfere with folate metabolism and potentially lead to folate deficiency?</span></span></p>",
      "unique_key": "Q2609539",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507532,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Methotrexate</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate is a dihydrofolate reductase inhibitor, interfering with folate metabolism and leading to functional folate deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Aspirin:</span></strong><span style=\"font-size:12.0pt\"> While aspirin can cause some minor interference with folate absorption at very high doses, it&#39;s not a major contributor to folate deficiency at typical doses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Metformin:</span></strong><span style=\"font-size:12.0pt\"> Metformin primarily affects glucose metabolism and doesn&#39;t have a direct impact on folate metabolism. However, long-term metformin use has been associated with mild decreases in vitamin B12 levels, which can sometimes be confused with folate deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Atorvastatin:</span></strong><span style=\"font-size:12.0pt\"> Atorvastatin is a cholesterol-lowering medication (statin) and does not interfere with folate metabolism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While all medications should be reviewed when a patient presents with folate deficiency, methotrexate stands out as the most likely culprit due to its direct inhibitory effect on dihydrofolate reductase, a key enzyme in folate metabolism.</span></span></span></p>",
      "correct_choice_id": 83145,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52823,
      "choices": [
        {
          "id": 210781,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Addition of N-acetylgalactosamine (GalNAc) to the H antigen </span></span></span></p>"
        },
        {
          "id": 210782,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Addition of galactose (Gal) to the H antigen </span></span></span></p>"
        },
        {
          "id": 210783,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Removal of fucose from the H antigen </span></span></span></p>"
        },
        {
          "id": 210784,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Absence of both GalNAc and Gal on the H antigen</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following genetic modifications on chromosome 9 leads to the formation of the B antigen?</span></span></p>",
      "unique_key": "Q1300662",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507533,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Addition of galactose (Gal) to the H antigen</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The B antigen is formed by the addition of a galactose molecule to the terminal end of the H antigen. This is facilitated by specific glycosyltransferases encoded on chromosome 9.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Addition of N-acetylgalactosamine (GalNAc) to the H antigen:</span></strong><span style=\"font-size:12.0pt\"> This modification results in the formation of the A antigen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Removal of fucose from the H antigen:</span></strong><span style=\"font-size:12.0pt\"> While removal of fucose is a step in the formation of both A and B antigens, it&#39;s not the final step for the B antigen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Absence of both GalNAc and Gal on the H antigen:</span></strong><span style=\"font-size:12.0pt\"> This results in the O blood group, where neither A nor B antigens are present.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The A and B antigens are formed by modifications of the H antigen.</span></span></span></p>",
      "correct_choice_id": 210782,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52828,
      "choices": [
        {
          "id": 210801,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Kell </span></span></span></p>"
        },
        {
          "id": 210802,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Kidd </span></span></span></p>"
        },
        {
          "id": 210803,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MNS </span></span></span></p>"
        },
        {
          "id": 210804,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lewis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient experiences a delayed hemolytic transfusion reaction (DHTR) 5 days after a blood transfusion. Which of the following blood group systems is most likely responsible?</span></span></p>",
      "unique_key": "Q2975726",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507534,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Kidd</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Kidd blood group system is known for its association with delayed hemolytic transfusion reactions (DHTR), often occurring days after the transfusion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Kell:</span></strong><span style=\"font-size:12.0pt\"> While Kell antibodies can cause severe hemolytic reactions, these are typically acute rather than delayed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. MNS:</span></strong><span style=\"font-size:12.0pt\"> MNS antibodies can cause delayed hemolytic transfusion reactions, but they are relatively rare compared to Kidd antibodies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lewis:</span></strong><span style=\"font-size:12.0pt\"> Lewis antibodies are naturally occurring and typically of the IgM isotype, which are generally not considered clinically significant in transfusions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Kidd antibodies are typically IgG and can cause severe delayed reactions.</span></span></span></p>",
      "correct_choice_id": 210802,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52830,
      "choices": [
        {
          "id": 210809,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">K/k</span></span></span></p>"
        },
        {
          "id": 210810,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DARC (Duffy Antigen Receptor for Chemokines)</span></span></span></p>"
        },
        {
          "id": 210811,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lewis Ag</span></span></span></p>"
        },
        {
          "id": 210812,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A antigen</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following antigen is resistant to P. vivax/knowlesi?</span></span></span></p>",
      "unique_key": "Q2684779",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507535,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) DARC (Duffy Antigen Receptor for Chemokines)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Duffy Antigen Receptor for Chemokines (DARC):&nbsp;</span></strong><span style=\"font-size:12.0pt\">The DARC acts as a receptor for both chemokines and <em>Plasmodium vivax</em> and <em>Plasmodium knowlesi</em> malaria parasites. Individuals lacking this receptor (Duffy-negative phenotype) are resistant to these types of malaria.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. K/k:</span></strong><span style=\"font-size:12.0pt\"> Kell antigens are a group of antigens found on red blood cells. They are not involved in malaria resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lewis Ag:</span></strong><span style=\"font-size:12.0pt\"> Lewis antigens are present in body fluids and can be adsorbed onto red blood cells. They do not play a role in malaria resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. A antigen:</span></strong><span style=\"font-size:12.0pt\"> The A antigen is part of the ABO blood group system and determines blood type. It has no relationship to malaria susceptibility.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Duffy antigen receptor for chemokines (DARC) is essential for <em>P. vivax</em> and <em>P. knowlesi</em> malaria parasites to invade red blood cells. Individuals without this receptor are naturally resistant to these types of malaria.</span></span></span></p>",
      "correct_choice_id": 210810,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52832,
      "choices": [
        {
          "id": 210817,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A+ </span></span></span></p>"
        },
        {
          "id": 210818,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">B+ </span></span></span></p>"
        },
        {
          "id": 210819,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AB+ </span></span></span></p>"
        },
        {
          "id": 210820,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">O-</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient&#39;s blood sample is mixed with Anit-A/B/D and the findings are shown below. What is the patient&#39;s blood type?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/01/screenshot-2024-08-01-103344.png\" style=\"height:164px; width:400px\" /></span></span></p>",
      "unique_key": "Q9219090",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507536,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) B+</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Agglutination with anti-B indicates the presence of B antigens on the red blood cells. Agglutination with anti-D indicates the presence of the Rh factor (positive). No agglutination with anti-A indicates the absence of A antigens.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Blood typing is determined by the presence or absence of specific antigens on the surface of red blood cells.</span></span></span></p>",
      "correct_choice_id": 210818,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20666,
      "choices": [
        {
          "id": 82627,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aplastic anemia</span></span></span></p>"
        },
        {
          "id": 82628,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immune thrombocytopenia (ITP)</span></span></span></p>"
        },
        {
          "id": 82629,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Myelodysplastic syndrome (MDS)</span></span></span></p>"
        },
        {
          "id": 82630,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombotic microangiopathy (TMA)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old woman presents to the clinic with a two-week history of easy bruising and pinprick red spots on her lower legs. She denies any recent injuries or medication use. On examination, she has multiple petechiae on her skin and mucous membranes. Blood investigations except low platelet count, imagings turned out to be normal. What&#39;s the likely diagnosis?</span></span></p>",
      "unique_key": "Q8541218",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507537,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Immune thrombocytopenia (ITP)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ITP is an autoimmune disorder characterized by isolated thrombocytopenia (low platelet count) with no other obvious cause. It is a common cause of thrombocytopenia in adults.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Aplastic anemia</span></strong><span style=\"font-size:12.0pt\">: While it can cause thrombocytopenia, it also affects other cell lines (red blood cells and white blood cells).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Myelodysplastic syndrome (MDS)</span></strong><span style=\"font-size:12.0pt\">: MDS can cause thrombocytopenia, but it is more common in older adults and often presents with other cytopenias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Thrombotic microangiopathy (TMA)</span></strong><span style=\"font-size:12.0pt\">: TMA causes thrombocytopenia through a different mechanism (platelet consumption in microvascular thrombi).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ITP is a diagnosis of exclusion, meaning other causes of thrombocytopenia need to be ruled out.</span></span></span></p>",
      "correct_choice_id": 82628,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20682,
      "choices": [
        {
          "id": 82691,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeat the CBC in a sodium citrate tube </span></span></span></p>"
        },
        {
          "id": 82692,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start corticosteroids for ITP </span></span></span></p>"
        },
        {
          "id": 82693,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Order a bone marrow biopsy </span></span></span></p>"
        },
        {
          "id": 82694,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Begin heparin therapy for HIT</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old asymptomatic woman has a routine complete blood count (CBC) which shows a platelet count of 80,000/&micro;L. Peripheral blood smear shows large platelet clumps. Given the likely diagnosis, Which of the following is the most appropriate next step in the management of this patient? </span></span></p>",
      "unique_key": "Q7335204",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507538,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Repeat the CBC in a sodium citrate tube</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeating the CBC in a sodium citrate tube is the most appropriate next step to confirm pseudothrombocytopenia. Citrate prevents platelet clumping and will show a normal platelet count if pseudothrombocytopenia is the cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Start corticosteroids for ITP</span></strong><span style=\"font-size:12.0pt\">: Corticosteroids are used to treat ITP, but this is not appropriate until pseudothrombocytopenia is ruled out.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Order a bone marrow biopsy</span></strong><span style=\"font-size:12.0pt\">: A bone marrow biopsy is not necessary for the diagnosis of pseudothrombocytopenia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Begin heparin therapy for HIT</span></strong><span style=\"font-size:12.0pt\">: Heparin therapy is contraindicated in HIT and should not be started until this diagnosis is ruled out.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeating the CBC in a citrate tube is a simple and effective way to confirm pseudothrombocytopenia.</span></span></span></p>",
      "correct_choice_id": 82691,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20691,
      "choices": [
        {
          "id": 82727,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary immune thrombocytopenia (ITP) </span></span></span></p>"
        },
        {
          "id": 82728,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Drug-induced thrombocytopenia </span></span></span></p>"
        },
        {
          "id": 82729,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heparin-induced thrombocytopenia (HIT) </span></span></span></p>"
        },
        {
          "id": 82730,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Secondary ITP associated with CLL</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old male with a recent diagnosis of chronic lymphocytic leukemia (CLL) presents with fatigue, easy bruising, and petechiae. His platelet count is 20,000/&micro;L. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q4749549",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507539,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Secondary ITP associated with CLL</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s recent diagnosis of CLL and the absence of any other obvious cause for thrombocytopenia point towards secondary ITP. CLL is a known cause of secondary ITP.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>A. Primary immune thrombocytopenia (ITP):</strong> While ITP presents with isolated thrombocytopenia, the presence of CLL suggests a secondary cause in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>B. Drug-induced thrombocytopenia:</strong> There is no mention of recent medication use to suggest this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Heparin-induced thrombocytopenia (HIT):</strong> HIT is an immune-mediated reaction to heparin, which is not mentioned in the patient&#39;s history.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Secondary ITP can be caused by various underlying conditions, including lymphoproliferative disorders like CLL.</span></span></span></p>",
      "correct_choice_id": 82730,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20697,
      "choices": [
        {
          "id": 82751,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab infusion </span></span></span></p>"
        },
        {
          "id": 82752,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Splenectomy </span></span></span></p>"
        },
        {
          "id": 82753,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Danazol therapy </span></span></span></p>"
        },
        {
          "id": 82754,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fostamatinib therapy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old woman with a 5-year history of chronic ITP has persistent thrombocytopenia (25,000/&micro;L) despite prior treatments with corticosteroids, IVIg, and TPO-RAs. She experiences frequent bleeding and seeks further management options. Which of the following is the next step in her management? </span></span></p>",
      "unique_key": "Q2274254",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507540,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Splenectomy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Splenectomy is considered the most effective second-line therapy for chronic ITP refractory to initial treatments. It offers the highest chance of long-term remission (up to 65%), as the spleen is the primary site of platelet destruction in ITP. However, it is a surgical procedure with associated risks, including infection and thrombosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Rituximab infusion:</strong> While rituximab can be effective in some patients, its response rate is lower than splenectomy and the onset of action is delayed. It also carries potential for serious side effects like infections and infusion reactions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Danazol therapy:</strong> Danazol is an older medication with limited evidence of efficacy in ITP and potential for masculinizing side effects in women, making it a less preferred option.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Fostamatinib therapy:</strong> This is a newer option with promising results, but it has less long-term data than splenectomy and may have adverse effects like hypertension, diarrhea, and hepatotoxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with chronic ITP refractory to initial therapies, splenectomy offers the highest chance of long-term remission, but it should be considered after weighing the risks and benefits of surgery. Other options like rituximab and fostamatinib may be considered in select cases, while danazol is less commonly used due to its limited efficacy and side effect profile.</span></span></span></p>",
      "correct_choice_id": 82752,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20708,
      "choices": [
        {
          "id": 82795,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immune Thrombocytopenic Purpura (ITP) </span></span></span></p>"
        },
        {
          "id": 82796,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type I Heparin-Induced Thrombocytopenia (HIT) </span></span></span></p>"
        },
        {
          "id": 82797,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type II Heparin-Induced Thrombocytopenia (HIT) </span></span></span></p>"
        },
        {
          "id": 82798,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombotic Thrombocytopenic Purpura (TTP)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old woman develops new-onset thrombocytopenia and thrombosis 6 days after initiating unfractionated heparin (UFH) for DVT prophylaxis following knee replacement surgery. Her medical history is significant for hypertension and osteoarthritis. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q5034633",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507541,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Type II Heparin-Induced Thrombocytopenia (HIT)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This is the most likely diagnosis given the temporal relationship between heparin initiation and the development of thrombocytopenia and thrombosis. Type II HIT is an immune-mediated reaction that typically occurs 5-14 days after heparin exposure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Immune Thrombocytopenic Purpura (ITP)</span></strong><span style=\"font-size:12.0pt\">: ITP is an autoimmune disorder that can cause thrombocytopenia but is not typically associated with thrombosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Type I Heparin-Induced Thrombocytopenia (HIT):</span></strong><span style=\"font-size:12.0pt\"> This is a non-immune mediated form of HIT that usually occurs within the first 2 days of heparin exposure and is not associated with thrombosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Thrombotic Thrombocytopenic Purpura (TTP):</span></strong><span style=\"font-size:12.0pt\"> TTP is a rare disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and neurologic symptoms. It is not typically associated with heparin use.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">New-onset thrombocytopenia and thrombosis in a patient recently started on heparin should raise suspicion for Type II HIT, which warrants immediate discontinuation of heparin and initiation of alternative anticoagulation.</span></span></span></p>",
      "correct_choice_id": 82797,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20713,
      "choices": [
        {
          "id": 82815,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombocytopenia </span></span></span></p>"
        },
        {
          "id": 82816,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microangiopathic hemolytic anemia (MAHA) </span></span></span></p>"
        },
        {
          "id": 82817,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prolonged PT and PTT </span></span></span></p>"
        },
        {
          "id": 82818,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Renal dysfunction</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a typical clinical feature of Thrombotic Microangiopathy (TMA)?</span></span></p>",
      "unique_key": "Q3300243",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507542,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Prolonged PT and PTT</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PT and PTT are usually normal in TMA, as it primarily affects platelet function and does not involve the coagulation cascade.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>Thrombocytopenia</strong>: A key feature of TMA due to platelet consumption in microthrombi.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;Microangiopathic hemolytic anemia (MAHA)</span></strong><span style=\"font-size:12.0pt\">: Also a key feature of TMA due to mechanical damage to red blood cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Renal</span></strong><span style=\"font-size:12.0pt\"> <strong>dysfunction</strong>: Can occur due to microthrombi formation in the kidneys.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal PT and PTT help differentiate TMA from other conditions like DIC, which typically present with abnormal coagulation tests.</span></span></span></p>",
      "correct_choice_id": 82817,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20714,
      "choices": [
        {
          "id": 82819,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TTP </span></span></span></p>"
        },
        {
          "id": 82820,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HUS </span></span></span></p>"
        },
        {
          "id": 82821,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DIC </span></span></span></p>"
        },
        {
          "id": 82822,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TMA</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with a history of malignant hypertension presents with MAHA, thrombocytopenia, and acute kidney injury. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q4989306",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507543,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) TMA</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malignant hypertension can cause TMA due to severe endothelial damage. The patient&#39;s history supports this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. TTP (Thrombotic Thrombocytopenic Purpura):</strong> While TTP can present with MAHA, thrombocytopenia, and acute kidney injury, it is typically associated with a deficiency of the ADAMTS13 enzyme. This patient&#39;s history of malignant hypertension makes TMA a more likely diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. HUS (Hemolytic Uremic Syndrome):</strong> HUS is often associated with Shiga-toxin producing E. coli infection and commonly presents with bloody diarrhea. The patient&#39;s history does not suggest this.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. DIC (Disseminated Intravascular Coagulation):</strong> DIC is a consumptive coagulopathy triggered by a systemic illness (e.g., sepsis, malignancy). While it can cause MAHA and thrombocytopenia, it would typically present with abnormal coagulation parameters (prolonged PT/PTT, low fibrinogen) which are not mentioned in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It&#39;s important to consider secondary causes of TMA, such as malignant hypertension, in patients with relevant risk factors.</span></span></span></p>",
      "correct_choice_id": 82822,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20716,
      "choices": [
        {
          "id": 82827,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CFH </span></span></span></p>"
        },
        {
          "id": 82828,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CFI </span></span></span></p>"
        },
        {
          "id": 82829,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD46 </span></span></span></p>"
        },
        {
          "id": 82830,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">STXBP5</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following genetic mutations is NOT typically associated with familial atypical HUS?</span></span></p>",
      "unique_key": "Q9008876",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507684,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) STXBP5</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While <em>STXBP5</em> mutations can cause aHUS, they are not typically associated with the familial form of the disease. This gene is more commonly involved in a rare neurological disorder called STXBP5-related epileptic encephalopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>A. CFH, Option</strong> <strong>B. CFI </strong>and<strong> Option</strong> <strong>C. CD46:</strong> These genes all encode complement regulatory proteins, and mutations in them can lead to familial aHUS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial atypical HUS is a genetically heterogeneous disorder with mutations in several complement regulatory genes. Recognizing the role of these genes is essential for accurate diagnosis, genetic counseling, and potential targeted therapies. While <em>STXBP5</em> mutations are more commonly associated with a neurological disorder and are not typically seen in familial cases.</span></span></span></p>",
      "correct_choice_id": 82830,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52814,
      "choices": [
        {
          "id": 210745,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methylmalonic acidemia due to MMACHC mutation </span></span></span></p>"
        },
        {
          "id": 210746,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dihydrofolate reductase (DHFR) deficiency </span></span></span></p>"
        },
        {
          "id": 210747,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Maple syrup urine disease (MSUD) </span></span></span></p>"
        },
        {
          "id": 210748,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tyrosinemia type I</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 4-month-old infant presents with lethargy, hypotonia, and developmental delay. Laboratory investigations reveal megaloblastic anemia, elevated homocysteine and methylmalonic acid (MMA) levels. Which of the following conditions is MOST LIKELY to predispose this infant to thrombotic microangiopathy (TMA)?</span></span></p>",
      "unique_key": "Q3915061",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507685,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Methylmalonic acidemia due to MMACHC mutation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methylmalonic acidemia (MMA) due to MMACHC mutation can lead to elevated homocysteine levels, which is a known risk factor for developing thrombotic microangiopathy (TMA). TMA is a serious condition characterized by microvascular thrombosis, resulting in organ damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Dihydrofolate reductase (DHFR) deficiency</span></strong><span style=\"font-size:12.0pt\">: DHFR deficiency primarily affects folate metabolism and does not directly predispose to TMA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Maple syrup urine disease (MSUD)</span></strong><span style=\"font-size:12.0pt\">: MSUD is an amino acid disorder and is not associated with increased risk of TMA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tyrosinemia type I</span></strong><span style=\"font-size:12.0pt\">: Tyrosinemia type I is a metabolic disorder affecting tyrosine metabolism and does not typically predispose to TMA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MMACHC mutations can lead to elevated homocysteine levels, which increases the risk of developing thrombotic microangiopathy (TMA) in affected individuals.</span></span></span></p>",
      "correct_choice_id": 210745,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20902,
      "choices": [
        {
          "id": 83572,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ristocetin cofactor activity </span></span></span></p>"
        },
        {
          "id": 83573,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platelet aggregation studies </span></span></span></p>"
        },
        {
          "id": 83574,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor VIII assay </span></span></span></p>"
        },
        {
          "id": 83575,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bone marrow biopsy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old female presents with a history of heavy menstrual bleeding since menarche. She also reports easy bruising and prolonged bleeding after minor cuts. Physical examination reveals scattered petechiae. Which of the following tests is most likely to be diagnostic?</span></span></p>",
      "unique_key": "Q3344899",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507686,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Platelet aggregation studies</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platelet aggregation studies are the most specific test for diagnosing Glanzmann thrombasthenia, a likely diagnosis based on the patient&#39;s history and physical examination. They will show absent or markedly reduced aggregation in response to multiple agonists.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ristocetin cofactor activity</span></strong><span style=\"font-size:12.0pt\">: This test measures the function of von Willebrand factor (vWF) and is used in the diagnosis of von Willebrand disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Factor VIII assay</span></strong><span style=\"font-size:12.0pt\">: This test is used to diagnose hemophilia A.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Bone marrow biopsy</span></strong><span style=\"font-size:12.0pt\">: This test is not indicated in the initial workup of suspected Glanzmann thrombasthenia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platelet aggregation studies are the definitive test for diagnosing Glanzmann thrombasthenia.</span></span></span></p>",
      "correct_choice_id": 83573,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52815,
      "choices": [
        {
          "id": 210749,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Staphylococcus aureus </span></span></span></p>"
        },
        {
          "id": 210750,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Streptococcus pneumoniae </span></span></span></p>"
        },
        {
          "id": 210751,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pseudomonas aeruginosa </span></span></span></p>"
        },
        {
          "id": 210752,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Candida albicans</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 4-year-old child presents with recurrent pyogenic skin and respiratory infections, silver-grey hair, and nystagmus. Peripheral blood smear reveals giant granules in neutrophils. Given the likely diagnosis, Which of the following infections is MOST frequently associated with this condition?</span></span></p>",
      "unique_key": "Q7455136",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507687,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Staphylococcus aureus</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with Chediak-Higashi syndrome are particularly susceptible to Staphylococcus aureus infections due to impaired neutrophil function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Streptococcus pneumoniae:</span></strong><span style=\"font-size:12.0pt\"> While patients with Chediak-Higashi syndrome may be more susceptible to infections in general, there isn&#39;t a specific predisposition towards Streptococcus pneumoniae compared to Staphylococcus aureus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pseudomonas aeruginosa:</span></strong><span style=\"font-size:12.0pt\"> Pseudomonas is more commonly associated with patients with cystic fibrosis or other immunocompromised states. It&#39;s not a hallmark infection for Chediak-Higashi.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Candida albicans:</span></strong><span style=\"font-size:12.0pt\"> This is a fungal infection, and while Chediak-Higashi syndrome patients may be more susceptible to infections overall, bacterial infections (especially those caused by Staphylococcus aureus) are of greater concern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recurrent Staphylococcus aureus infections are a hallmark of Chediak-Higashi syndrome.</span></span></span></p>",
      "correct_choice_id": 210749,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52818,
      "choices": [
        {
          "id": 210761,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Von Willebrand disease (VWD) type 1 </span></span></span></p>"
        },
        {
          "id": 210762,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Von Willebrand disease (VWD) type 2 </span></span></span></p>"
        },
        {
          "id": 210763,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Von Willebrand disease (VWD) type 3 </span></span></span></p>"
        },
        {
          "id": 210764,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acquired von Willebrand syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old man with a history of easy bruising and prolonged bleeding after minor procedures undergoes laboratory testing. The results reveal a normal von Willebrand factor (vWF) antigen level, but a decreased vWF ristocetin cofactor activity (RCoF). Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q3216491",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507688,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Von Willebrand disease (VWD) type 2</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This type of VWD is characterized by qualitative defects in vWF. While the quantity of vWF (antigen level) may be normal, its function (RCoF) is impaired, leading to bleeding problems.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Von Willebrand disease (VWD) type 1:</span></strong><span style=\"font-size:12.0pt\"> In VWD type 1, both vWF antigen and RCoF levels are decreased proportionally, not just the RCoF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Von Willebrand disease (VWD) type 3:</span></strong><span style=\"font-size:12.0pt\"> This is the most severe form of VWD with a near-complete absence of vWF, so both antigen and RCoF would be very low.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Acquired von Willebrand syndrome:</span></strong><span style=\"font-size:12.0pt\"> While this can mimic VWD, it is usually associated with underlying conditions like lymphoproliferative disorders, autoimmune diseases, or certain medications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A normal vWF antigen level with a decreased RCoF strongly suggests a qualitative defect in vWF, which is characteristic of VWD type 2. Further testing can determine the specific subtype (2A, 2B, 2M, or 2N).</span></span></span></p>",
      "correct_choice_id": 210762,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53093,
      "choices": [
        {
          "id": 211861,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor VIII only </span></span></span></p>"
        },
        {
          "id": 211862,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor IX only </span></span></span></p>"
        },
        {
          "id": 211863,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Both Factor VIII and von Willebrand Factor (vWF) </span></span></span></p>"
        },
        {
          "id": 211864,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor VIII, vWF, and Factor IX</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following coagulation factors are increased by the administration of DDAVP?</span></span></p>",
      "unique_key": "Q8417043",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507689,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Both Factor VIII and von Willebrand Factor (vWF)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Desmopressin (DDAVP) acts by stimulating the release of both Factor VIII and von Willebrand factor (vWF) from storage sites within endothelial cells. This leads to a temporary increase in their levels in the blood, aiding in clot formation and controlling bleeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Factor VIII only</span></strong><span style=\"font-size:12.0pt\">: While DDAVP does increase Factor VIII, it also increases vWF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Factor IX only</span></strong><span style=\"font-size:12.0pt\">: DDAVP does not affect Factor IX levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Factor VIII, vWF, and Factor IX</span></strong><span style=\"font-size:12.0pt\">: This is incorrect because, as mentioned above, DDAVP does not affect Factor IX levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DDAVP is a useful therapeutic agent in certain bleeding disorders, particularly mild hemophilia A and some types of von Willebrand disease (VWD), due to its ability to increase the levels of both Factor VIII and vWF. Understanding its mechanism of action is crucial for selecting appropriate patients for treatment and anticipating its effects.</span></span></span></p>",
      "correct_choice_id": 211863,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53085,
      "choices": [
        {
          "id": 211829,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Evasive behavior when asked about the hematomas</span></span></span></p>"
        },
        {
          "id": 211830,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">History of spontaneous hematomas in paternal grandmother</span></span></span></p>"
        },
        {
          "id": 211831,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Petechiae in the oropharynx</span></span></span></p>"
        },
        {
          "id": 211832,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intraarticular iron deposition</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 22-year-old man with a history of frequent nosebleeds and prolonged bleeding after a tooth extraction presents with recurrent, painless bloody urine. Examination reveals multiple hematomas and decreased range of motion with crepitus in both ankles. Laboratory studies show a normal platelet count, prolonged partial thromboplastin time (PTT), and hematuria without RBC casts. An&nbsp;x-ray&nbsp;of the pelvis shows no abnormalities. Further evaluation of this patient is most likely to show which of the following findings?</span></span></p>",
      "unique_key": "Q2758937",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507690,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Intraarticular iron deposition</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeated hemarthrosis (bleeding into joints) is a hallmark of hemophilia. This leads to iron deposition within the joint (hemosiderin) due to the breakdown of red blood cells. Over time, this iron can cause synovitis and cartilage damage, resulting in chronic joint problems and a decreased range of motion, as seen in this patient. An MRI or ultrasound would be the best way to confirm this finding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Evasive behavior when asked about the hematomas:</span></strong><span style=\"font-size:12.0pt\"> While this might be present in some cases, it&#39;s not specific to hemophilia and doesn&#39;t help confirm the diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. History of spontaneous hematomas in paternal grandmother:</span></strong><span style=\"font-size:12.0pt\"> While hemophilia is often inherited, a family history alone is not enough to diagnose the condition. Direct testing for factor deficiencies is needed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Petechiae in the oropharynx:</span></strong><span style=\"font-size:12.0pt\"> Petechiae are typically associated with thrombocytopenia (low platelet count), not hemophilia. This patient&#39;s platelet count is normal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In a patient with suspected hemophilia, further evaluation with imaging studies like MRI or ultrasound is essential to assess joint damage and confirm the diagnosis of hemophilic arthropathy. A positive family history can raise suspicion, but definitive diagnosis requires factor assays.</span></span></span></p>",
      "correct_choice_id": 211832,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53096,
      "choices": [
        {
          "id": 211873,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor VIII gene mutation </span></span></span></p>"
        },
        {
          "id": 211874,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factor V gene mutation </span></span></span></p>"
        },
        {
          "id": 211875,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">LMAN1 gene mutation </span></span></span></p>"
        },
        {
          "id": 211876,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prothrombin gene mutation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old male presents with a history of mild bleeding tendencies since childhood, primarily after trauma or surgery. He is found to have prolonged PT and aPTT, both of which correct with mixing studies. Which of the following genetic mutations is most likely associated with his condition?</span></span></p>",
      "unique_key": "Q6084461",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507691,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) LMAN1 gene mutation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation and laboratory findings are consistent with combined factor V and factor VIII deficiency, a rare autosomal recessive disorder caused by mutations in the LMAN1 gene.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Factor VIII gene mutation</span></strong><span style=\"font-size:12.0pt\">: Causes hemophilia A, with isolated prolongation of aPTT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Factor V gene mutation</span></strong><span style=\"font-size:12.0pt\">: Causes factor V deficiency, with isolated prolongation of PT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prothrombin gene mutation</span></strong><span style=\"font-size:12.0pt\">: Causes prothrombin deficiency, with isolated prolongation of PT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Combined factor V and factor VIII deficiency is associated with mutations in the LMAN1 gene, leading to mild bleeding tendencies.</span></span></span></p>",
      "correct_choice_id": 211875,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53052,
      "choices": [
        {
          "id": 211697,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">ACD (Acid citrate dextrose) </span></span></span></p>"
        },
        {
          "id": 211698,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CPD (Citrate phosphate dextrose) </span></span></span></p>"
        },
        {
          "id": 211699,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CP2D (Citrate phosphate double dextrose) </span></span></span></p>"
        },
        {
          "id": 211700,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SAGM (Saline adenine glucose mannitol)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which blood additive provides the longest shelf life for stored red blood cells?</span></span></span></p>",
      "unique_key": "Q5192868",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507692,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) SAGM (Saline adenine glucose mannitol)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The table shows that SAGM has a shelf life of 42 days, which is the longest among the listed additives. This is due to the presence of adenine and mannitol, which help to maintain red blood cell viability during storage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. ACD (Acid citrate dextrose):</span></strong><span style=\"font-size:12.0pt\"> This was one of the earliest preservatives and has a relatively short shelf life (21 days). The citrate acts as an anticoagulant, while dextrose provides energy for the red blood cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CPD (Citrate phosphate dextrose):</span></strong><span style=\"font-size:12.0pt\"> This is an improvement over ACD due to the addition of phosphate, which acts as a buffer to maintain pH. However, it still has a relatively short shelf life (21 days).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. CP2D (Citrate phosphate double dextrose):</span></strong><span style=\"font-size:12.0pt\"> This has double the amount of dextrose compared to CPD, providing more energy for the red blood cells and extending the shelf life slightly (28 days).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SAGM is the additive that provides the longest shelf life for stored red blood cells.</span></span></span></p>",
      "correct_choice_id": 211700,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53054,
      "choices": [
        {
          "id": 211705,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lower cost </span></span></span></p>"
        },
        {
          "id": 211706,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced risk of alloimmunization </span></span></span></p>"
        },
        {
          "id": 211707,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Higher platelet increment </span></span></span></p>"
        },
        {
          "id": 211708,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Longer shelf life</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the main advantage of single-donor platelets (SDPs) over random-donor platelets (RDPs)?</span></span></p>",
      "unique_key": "Q7415331",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507693,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Reduced risk of alloimmunization</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SDPs are derived from a single donor, reducing the number of donor exposures and, therefore, the risk of alloimmunization (development of antibodies against foreign platelet antigens).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Lower cost:</span></strong><span style=\"font-size:12.0pt\"> SDPs are typically more expensive to produce than RDPs because they require apheresis, a specialized blood collection procedure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Higher platelet increment:</span></strong><span style=\"font-size:12.0pt\"> While some studies have shown slightly higher platelet increments with SDPs, the difference is not always clinically significant, and the overall efficacy in preventing bleeding is similar between SDPs and RDPs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Longer shelf life:</span></strong><span style=\"font-size:12.0pt\"> Both SDPs and RDPs have similar shelf lives, typically around 5 days when stored properly.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SDPs are preferred to reduce the risk of alloimmunization in patients who may require multiple transfusions.</span></span></span></p>",
      "correct_choice_id": 211706,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53057,
      "choices": [
        {
          "id": 211717,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cryoprecipitate</span></span></span></p>"
        },
        {
          "id": 211718,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prothrombin complex concentrate (PCC)</span></span></span></p>"
        },
        {
          "id": 211719,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fresh frozen plasma (FFP)</span></span></span></p>"
        },
        {
          "id": 211720,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platelet concentrate</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with severe liver disease presents with a prolonged prothrombin time (PT) and is scheduled for an invasive procedure. Which of the following is the most appropriate blood product for correcting their coagulopathy?</span></span></p>",
      "unique_key": "Q6656450",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507694,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Fresh frozen plasma (FFP)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">FFP contains all coagulation factors and is the most appropriate choice for correcting multiple factor deficiencies in liver disease. Cryoprecipitate contains fibrinogen and factor VIII, PCC contains vitamin K-dependent factors, and platelets are used for thrombocytopenia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cryoprecipitate:</span></strong><span style=\"font-size:12.0pt\"> While cryoprecipitate is a source of fibrinogen and factor VIII, it would not address the multiple coagulation factor deficiencies commonly seen in liver disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Prothrombin Complex Concentrate (PCC):</span></strong><span style=\"font-size:12.0pt\"> PCC contains vitamin K-dependent clotting factors (II, VII, IX, and X), but patients with liver disease may also have deficiencies in other factors not included in PCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Platelet concentrate:</span></strong><span style=\"font-size:12.0pt\"> Platelets are used to treat thrombocytopenia (low platelet count), not coagulation factor deficiencies. While liver disease can cause thrombocytopenia, it is not the primary concern in this scenario where the patient has a prolonged PT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">FFP is the preferred blood product for correcting coagulopathy in liver disease due to its comprehensive coagulation factor content.</span></span></span></p>",
      "correct_choice_id": 211719,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53062,
      "choices": [
        {
          "id": 211737,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Irradiation of RBCs </span></span></span></p>"
        },
        {
          "id": 211738,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Washing of RBCs </span></span></span></p>"
        },
        {
          "id": 211739,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">UVB-treated RBCs </span></span></span></p>"
        },
        {
          "id": 211740,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Plasmapheresis of RBCs</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with a history of severe febrile non-hemolytic transfusion reactions (FNHTR) is scheduled for surgery and requires a red blood cell (RBC) transfusion. The blood bank is unable to provide leukoreduced RBCs due to limited supply. Which of the following alternative methods could be considered to potentially reduce the risk of FNHTR in this patient?</span></span></p>",
      "unique_key": "Q7163239",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507695,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) UVB-treated RBCs</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">UVB-treated RBCs have been investigated as a potential alternative to leukoreduction in reducing the risk of FNHTR. While leukoreduction is the standard approach, UVB treatment may offer a similar benefit by inactivating white blood cells and reducing cytokine release.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Irradiation of RBCs:</span></strong><span style=\"font-size:12.0pt\"> Irradiation is primarily used to prevent transfusion-associated graft-versus-host disease (TA-GVHD) in immunocompromised patients. It does not specifically address the risk of FNHTR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Washing of RBCs:</span></strong><span style=\"font-size:12.0pt\"> Washing RBCs can remove some plasma proteins and antibodies, which may be helpful in preventing allergic reactions. However, it is not as effective as leukoreduction in preventing FNHTR, which is primarily caused by cytokines released from white blood cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Plasmapheresis of RBCs:</span></strong><span style=\"font-size:12.0pt\"> Plasmapheresis is a procedure that separates plasma from blood cells and is not relevant to reducing the risk of FNHTR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">UVB-treated RBCs may be considered as an alternative to leukoreduced RBCs in situations where leukoreduction is not feasible or unavailable. However, the efficacy of UVB treatment in preventing FNHTR is still under investigation.</span></span></span></p>",
      "correct_choice_id": 211739,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20598,
      "choices": [
        {
          "id": 82355,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folate deficiency </span></span></span></p>"
        },
        {
          "id": 82356,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron deficiency anemia </span></span></span></p>"
        },
        {
          "id": 82357,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemolytic anemia </span></span></span></p>"
        },
        {
          "id": 82358,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anemia of chronic disease</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male with a history of chronic kidney disease presents with fatigue and shortness of breath. His laboratory findings show a MCV 88 fL with a low reticulocyte production index (RPI &lt; 2). Which of the following is the MOST likely cause of his anemia?</span></span></p>",
      "unique_key": "Q6200976",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507696,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Anemia of chronic disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic kidney disease is a classic cause of anemia of chronic disease, characterized by normocytic anemia with low RPI due to impaired erythropoietin production and iron utilization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Folate deficiency:</span></strong><span style=\"font-size:12.0pt\"> Macrocytic anemia with high RPI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Iron deficiency anemia:</span></strong><span style=\"font-size:12.0pt\"> Microcytic anemia with low RPI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hemolytic anemia:</span></strong><span style=\"font-size:12.0pt\"> Normocytic/macrocytic anemia with high RPI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normocytic anemia with low RPI in the setting of chronic disease should prompt consideration of anemia of chronic disease.</span></span></span></p>",
      "correct_choice_id": 82358,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20600,
      "choices": [
        {
          "id": 82363,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anemia of chronic disease (ACD) </span></span></span></p>"
        },
        {
          "id": 82364,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Iron deficiency anemia (IDA) </span></span></span></p>"
        },
        {
          "id": 82365,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Thalassemia trait </span></span></span></p>"
        },
        {
          "id": 82366,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Sideroblastic anemia (SA)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man with a history of rheumatoid arthritis presents with fatigue and a normocytic anemia (MCV 90 fL). His iron studies show the following:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum iron: 30 mcg/dL (normal: 60-170 mcg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TIBC: 200 mcg/dL (normal: 240-450 mcg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ferritin: 350 ng/mL (normal: 20-500 ng/mL)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q7331894",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507697,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Anemia of chronic disease (ACD)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Anemia of chronic disease (ACD):</span></strong><span style=\"font-size:12.0pt\"> This patient&#39;s presentation and lab values are consistent with ACD. The inflammatory response in rheumatoid arthritis disrupts iron metabolism, leading to low serum iron and TIBC, despite adequate iron stores (as indicated by the normal to elevated ferritin).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Iron deficiency anemia (IDA):</span></strong><span style=\"font-size:12.0pt\"> IDA would typically present with low serum iron, high TIBC, and low ferritin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Thalassemia trait:</span></strong><span style=\"font-size:12.0pt\"> This is a genetic condition causing microcytic anemia, not normocytic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sideroblastic anemia (SA):</span></strong><span style=\"font-size:12.0pt\"> SA is less likely in this scenario as it often presents with elevated serum iron and ferritin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the distinct pattern of iron studies in anemia of chronic disease (low serum iron, low TIBC, and normal to elevated ferritin) is crucial for differentiating it from iron deficiency anemia.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the setting of a chronic inflammatory condition like rheumatoid arthritis, anemia of chronic disease is a common consideration.</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 82363,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20620,
      "choices": [
        {
          "id": 82443,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal serum iron, normal TIBC, and normal ferritin </span></span></span></p>"
        },
        {
          "id": 82444,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low serum iron, high TIBC, and low ferritin </span></span></span></p>"
        },
        {
          "id": 82445,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low serum iron, low TIBC, and high ferritin </span></span></span></p>"
        },
        {
          "id": 82446,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High serum iron, normal TIBC, and high ferritin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old woman with heavy menstrual bleeding presents with fatigue and pallor. Her lab results show a microcytic anemia with an elevated red cell distribution width and a low reticulocyte count. Which of the following laboratory findings would MOST likely be seen in this patient?</span></span></p>",
      "unique_key": "Q3229315",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507698,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Low serum iron, high TIBC, and low ferritin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation and laboratory findings are consistent with iron deficiency anemia (IDA). In IDA, iron stores are depleted, leading to low serum iron and ferritin levels. The body attempts to compensate by increasing iron binding capacity (TIBC).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of microcytic anemia, elevated RDW, and low reticulocyte count with low serum iron, high TIBC, and low ferritin strongly suggests iron deficiency anemia.</span></span></span></p>",
      "correct_choice_id": 82444,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20626,
      "choices": [
        {
          "id": 82467,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron deficiency anemia </span></span></span></p>"
        },
        {
          "id": 82468,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anemia of chronic disease </span></span></span></p>"
        },
        {
          "id": 82469,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-thalassemia trait </span></span></span></p>"
        },
        {
          "id": 82470,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alpha-thalassemia trait</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 28-year-old woman of Mediterranean descent is found to have mild microcytic anemia on routine blood work. Her iron studies are normal, and hemoglobin electrophoresis reveals an elevated HbA2 level. Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q1226679",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507699,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. C) Beta-thalassemia trait</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microcytic anemia with normal iron studies and elevated HbA2 on electrophoresis are characteristic of beta-thalassemia trait.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Iron deficiency anemia (IDA):</span></strong><span style=\"font-size:12.0pt\"> While IDA is the most common cause of microcytic anemia, it would typically present with abnormal iron studies (low serum iron, low ferritin, and high total iron-binding capacity).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Anemia of chronic disease (ACD):</span></strong><span style=\"font-size:12.0pt\"> ACD is typically normocytic, but can occasionally be microcytic. However, it would not typically cause elevated HbA2 levels on electrophoresis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Alpha-thalassemia trait:</span></strong><span style=\"font-size:12.0pt\"> Alpha thalassemia is another inherited disorder that can cause microcytic anemia, but it would not typically cause elevated HbA2 levels. Instead, it may be associated with an elevated HbH level or a normal hemoglobin electrophoresis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-thalassemia is a common cause of microcytic anemia in individuals of Mediterranean descent. Hemoglobin electrophoresis is essential for diagnosis.</span></span></span></p>",
      "correct_choice_id": 82469,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53063,
      "choices": [
        {
          "id": 211741,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Plasmapheresis </span></span></span></p>"
        },
        {
          "id": 211742,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corticosteroids </span></span></span></p>"
        },
        {
          "id": 211743,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous immunoglobulin (IVIG) </span></span></span></p>"
        },
        {
          "id": 211744,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old woman presents with a history of recurrent bacterial infections and is found to have low IgG levels. Which of the following is the most appropriate treatment option for her condition?</span></span></p>",
      "unique_key": "Q5003344",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507700,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Intravenous immunoglobulin (IVIG)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation suggests a primary immunodeficiency disorder characterized by hypogammaglobulinemia (low IgG levels). IVIG is the mainstay of treatment for such conditions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Plasmapheresis:</span></strong><span style=\"font-size:12.0pt\"> This is used to remove harmful substances from blood and is not indicated in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Corticosteroids:</span></strong><span style=\"font-size:12.0pt\"> While corticosteroids have immunomodulatory effects, they are not the first-line treatment for hypogammaglobulinemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Rituximab:</span></strong><span style=\"font-size:12.0pt\"> This is a monoclonal antibody targeting CD20-positive B cells and is not indicated for primary immunodeficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IVIG is a crucial therapy for patients with primary immunodeficiencies, providing passive immunity by supplementing IgG levels.</span></span></span></p>",
      "correct_choice_id": 211743,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20567,
      "choices": [
        {
          "id": 82230,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MDS is a clonal hematopoietic stem cell disorder. </span></span></span></p>"
        },
        {
          "id": 82231,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most patients with MDS will eventually progress to acute myeloid leukemia (AML). </span></span></span></p>"
        },
        {
          "id": 82232,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The risk of transformation to AML is higher in patients with complex karyotype abnormalities. </span></span></span></p>"
        },
        {
          "id": 82233,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Allogeneic stem cell transplantation is the only curative option for MDS.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about myelodysplastic syndromes (MDS) is FALSE?</span></span></p>",
      "unique_key": "Q9094610",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507701,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Most patients with MDS will eventually progress to acute myeloid leukemia (AML).</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While MDS can transform into AML, the majority of patients do not progress to AML. The risk of transformation depends on several factors, including the subtype of MDS and the presence of cytogenetic abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Not all MDS patients progress to AML, and the prognosis varies depending on several factors.</span></span></span></p>",
      "correct_choice_id": 82231,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20569,
      "choices": [
        {
          "id": 82238,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Very low </span></span></span></p>"
        },
        {
          "id": 82239,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low </span></span></span></p>"
        },
        {
          "id": 82240,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intermediate </span></span></span></p>"
        },
        {
          "id": 82241,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old male presents with fatigue, weakness, and easy bruising. Peripheral blood smear shows macrocytic anemia and dysplastic neutrophils. Cytogenetic analysis reveals a deletion in the long arm of chromosome 5 (del(5q)). According to the IPSS-R, what is the patient&#39;s prognostic risk category?</span></span></p>",
      "unique_key": "Q8819675",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507702,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Low</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of del(5q) is associated with a good prognosis in MDS, and the patient&#39;s age and blood count findings suggest a lower-risk disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Very Low:</span></strong><span style=\"font-size:12.0pt\"> While del(5q) MDS is a lower-risk subtype, it doesn&#39;t fall into the &quot;very low&quot; category, which is usually reserved for patients with very few cytopenias and no cytogenetic abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Intermediate:</span></strong><span style=\"font-size:12.0pt\"> This category typically includes patients with more cytopenias or less favorable cytogenetic findings than those with isolated del(5q).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. High:</span></strong><span style=\"font-size:12.0pt\"> These categories are reserved for MDS with a high risk of progression to acute myeloid leukemia (AML), which is not typical of isolated del(5q). These patients usually have excess blasts in the bone marrow, complex karyotypes, or specific genetic mutations associated with worse outcomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Del(5q) is a favorable cytogenetic abnormality in MDS associated with a better prognosis.</span></span></span></p>",
      "correct_choice_id": 82239,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20571,
      "choices": [
        {
          "id": 82246,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">JAK2 V617F </span></span></span></p>"
        },
        {
          "id": 82247,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BCR-ABL1</span></span></span></p>"
        },
        {
          "id": 82248,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">FLT3-ITD </span></span></span></p>"
        },
        {
          "id": 82249,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(15;17)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man presents with fatigue, weight loss, and abdominal fullness. Physical examination reveals splenomegaly. Peripheral blood smear shows a leukocytosis with left shift. Which of the following genetic abnormalities is most likely to be found in this patient?</span></span></p>",
      "unique_key": "Q9367075",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507703,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) BCR-ABL1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation of fatigue, weight loss, splenomegaly, and leukocytosis with left shift, strongly suggests chronic myeloid leukemia (CML). The BCR-ABL1 fusion gene is the hallmark of CML and results from a reciprocal translocation between chromosomes 9 and 22.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. JAK2 V617F</span></strong><span style=\"font-size:12.0pt\">: Associated with myeloproliferative neoplasms (MPNs) like polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. FLT3-ITD</span></strong><span style=\"font-size:12.0pt\">: More commonly associated with acute myeloid leukemia (AML).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. t(15;17)</span></strong><span style=\"font-size:12.0pt\">: Associated with acute promyelocytic leukemia (APL), a subtype of AML.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BCR-ABL1 fusion gene is the diagnostic hallmark of CML.</span></span></span></p>",
      "correct_choice_id": 82247,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20574,
      "choices": [
        {
          "id": 82258,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">JAK2 V617F mutation </span></span></span></p>"
        },
        {
          "id": 82259,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(15;17) translocation </span></span></span></p>"
        },
        {
          "id": 82260,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(9;22) translocation (Philadelphia chromosome) </span></span></span></p>"
        },
        {
          "id": 82261,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(8;21) translocation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the diagnostic hallmark of chronic myeloid leukemia (CML)?</span></span></p>",
      "unique_key": "Q1705421",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507704,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) t(9;22) translocation (Philadelphia chromosome)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Philadelphia chromosome, resulting from the t(9;22) translocation, is the characteristic genetic abnormality found in virtually all cases of CML.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. JAK2 V617F mutation</span></strong><span style=\"font-size:12.0pt\">: This mutation is associated with myeloproliferative neoplasms (MPNs), not CML.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. t(15;17) translocation</span></strong><span style=\"font-size:12.0pt\">: This translocation is the hallmark of acute promyelocytic leukemia (APL).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. t(8;21) translocation</span></strong><span style=\"font-size:12.0pt\">: This translocation is associated with acute myeloid leukemia (AML).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Philadelphia chromosome is the defining genetic feature of CML.</span></span></span></p>",
      "correct_choice_id": 82260,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20586,
      "choices": [
        {
          "id": 82307,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">inv(16) </span></span></span></p>"
        },
        {
          "id": 82308,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(15;17) </span></span></span></p>"
        },
        {
          "id": 82309,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">t(8;21) </span></span></span></p>"
        },
        {
          "id": 82310,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">-5/del(5q)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following cytogenetic abnormalities is associated with a high risk of relapse in AML?</span></span></p>",
      "unique_key": "Q5015017",
      "question_audio": null,
      "question_video": null,
      "map_id": 16507705,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) -5/del(5q)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Monosomy 5 or deletion of the long arm of chromosome 5 (5q-) is associated with a poor prognosis in AML and a high risk of relapse.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. inv(16):</span></strong><span style=\"font-size:12.0pt\"> This inversion is associated with acute myeloid leukemia with abnormal eosinophils (AML M4Eo) and generally has a favorable prognosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. t(15;17):</span></strong><span style=\"font-size:12.0pt\"> This translocation is the hallmark of acute promyelocytic leukemia (APL), a subtype of AML. APL has a good prognosis when treated promptly with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. t(8;21):</span></strong><span style=\"font-size:12.0pt\"> This translocation is associated with acute myeloid leukemia with maturation (AML M2) and also has a relatively favorable prognosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytogenetic abnormalities can significantly impact prognosis and treatment choices in AML.</span></span></span></p>",
      "correct_choice_id": 82310,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}